{"organizations": [], "uuid": "a8f5e38fe19abb6ae9a2c5e25c8d59ae9eac0f8d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/nabriva-study/nabrivas-pneumonia-drug-succeeds-in-late-stage-study-idUSL3N1SS3XF", "country": "US", "domain_rank": 408, "title": "Nabriva's pneumonia drug succeeds in late-stage study", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-21T14:36:00.000+03:00", "replies_count": 0, "uuid": "a8f5e38fe19abb6ae9a2c5e25c8d59ae9eac0f8d"}, "author": "", "url": "https://www.reuters.com/article/nabriva-study/nabrivas-pneumonia-drug-succeeds-in-late-stage-study-idUSL3N1SS3XF", "ord_in_thread": 0, "title": "Nabriva's pneumonia drug succeeds in late-stage study", "locations": [], "entities": {"persons": [{"name": "nabriva", "sentiment": "negative"}, {"name": "manas mishra", "sentiment": "none"}, {"name": "sai sachin ravikumar", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "nabriva", "sentiment": "negative"}, {"name": "nabriva therapeutics plc", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 21, 2018 / 11:38 AM / Updated 6 minutes ago Nabriva's pneumonia drug succeeds in late-stage study\nMay 21 (Reuters) - Nabriva Therapeutics Plc said on Monday its drug to treat adults suffering from a type of pneumonia met the main goal of a late-stage study.\nThe company plans to submit a marketing application for the drug, lefamulin, with the U.S. Food and Drug Administration in the fourth quarter of the year. (Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar)", "external_links": [], "published": "2018-05-21T14:36:00.000+03:00", "crawled": "2018-05-21T14:49:43.008+03:00", "highlightTitle": ""}